13 news items
HC Wainwright & Co. Reiterates Buy on Black Diamond Therapeutic, Maintains $11 Price Target
BDTX
7 Jun 24
HC Wainwright & Co. analyst Robert Burns reiterates Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and maintains $11 price target.
Reported Saturday, Black Diamond Therapeutics Showcased BDTX-1535 Clinical Data In Patients With Recurrent Glioblastoma At 2024 ASCO Annual Meeting
BDTX
3 Jun 24
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
BDTX
1 Jun 24
) -- Black Diamond Therapeutics, Inc
HC Wainwright & Co. Maintains Buy on Black Diamond Therapeutic, Lowers Price Target to $11
BDTX
16 May 24
HC Wainwright & Co. analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and lowers the price target from $12 to $11.
Black Diamond Therapeutic Q1 2024 GAAP EPS $(0.35) Beats $(0.44) Estimate
BDTX
9 May 24
Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.35
oh5ffgq3hvloljco8t
BDTX
9 May 24
NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage
rl175wb
ADAP
BDTX
DVA
23 Apr 24
physician services, and later became a founding Board member of Black Diamond Therapeutics
17dq3hfz6
BDTX
8 Apr 24
Wedbush analyst Robert Driscoll maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Outperform and raises the price target from $10 to $16.
nxg2 6xel
BDTX
8 Apr 24
hb8e6azqwq46q4ksiqzvoypl7acs72wmsr89 1b5
BDTX
3 Apr 24
) -- Black Diamond Therapeutics, Inc
tp2e983ifkmt6piqkysote
BDTX
13 Mar 24
Wedbush analyst Robert Driscoll reiterates Black Diamond Therapeutic (NASDAQ:BDTX) with a Outperform and maintains $10 price target.
c275xwo5nfbozan357uvcr9x8sb7mi2 wpk7cvnu69790
BDTX
12 Mar 24
Black Diamond Therapeutic (NASDAQ:BDTX) reported its Q4
huld6yzil9qx6ra1 h9k1b9gzlo
BDTX
12 Mar 24
Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.34
- Prev
- 1
- Next